CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Ultivue, een ontwikkelaar van identificatie- en kwantificeringstesten voor weefselbiomarkers voor translationeel onderzoek en pathologielaboratoria, heeft vandaag twee nieuwe toevoegingen aangekondigd aan zijn bestaande UltiMapper-platform voor onderzoek naar multiplexfluorescentie-immunohistochemie. De eerste, de UltiMapper I/O APC-kit, identificeert professionele antigeen-presenterende celtypen, inclusief dendritische cellen, macrofagen en B-cellen, en functies die verband houden met de initiatie en het onderhoud van de immuunrespons. De ander, de UltiMapper I/O T-act-kit, kwantificeert de proliferatieve tumorindex en bepaalt de cytotoxische T-celactiviteit en het vermogen ervan om apoptose te induceren.
Deze nieuwe kits hebben dezelfde voordelen van ‘high-throughput whole-slide imaging’, met behulp van conventionele IHC-apparatuur en workflows, als de eerder uitgebrachte UltiMapper I/O PD-L1 en UltiMapper I/O PD-1 kits, die infiltratie en uitputting van T-cellen identificeren.
Ultivue Expands UltiMapper™ Platform of Multiplex Assays for Tissue Immuno-Profiling
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue, a developer of tissue biomarker identification and quantification assays for translational research and pathology labs, today announced two new additions to its existing UltiMapper platform of multiplex fluorescence immunohistochemistry research kits. The UltiMapper I/O APC kit identifies professional antigen presenting cell types including dendritic cells, macrophages and B cells, and functions related to immune response initiation and maintenance. The UltiMapper I/O T-act kit quantifies the proliferative tumor index and determines cytotoxic T cell activity and its potential to induce apoptosis.
These new kits have the same benefits of high-throughput whole-slide imaging using conventional IHC equipment and workflows as the previously released UltiMapper I/O PD-L1 and UltiMapper I/O PD-1 kits that identify T-cell infiltration and exhaustion.
“By harnessing the unique capability of our proprietary InSituPlex® technology to simultaneously and accurately detect multiple markers on individual cells, our expanded UltiMapper platform of kits now allows researchers to characterize over 30 critical cell phenotypes commonly described in the tumor microenvironment,” said Philippe Mourere, Senior VP of Commercial Operations. “Throughout 2019, Ultivue will release new assays to meet the growing market demand for its UltiMapper platform of reagents. We are increasing the breadth and depth of immuno-profiling markers in tissue samples to support the validation of clinically-relevant biomarkers in immuno-oncology, inflammation & immunology, and cancer research.”
Researchers can now engage with Ultivue for access to the expanded platform of UltiMapper kits for on-site evaluation and implementation. In addition, Ultivue offers contract IHC services through the Ultivue Services Lab. For higher levels of biomarker multiplexing and custom reagent development, contact Ultivue’s Business Development team.
By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools. Ultivue is expanding its UltiMapper assay product portfolio and menu of contract research services to provide a comprehensive set of precision medicine solutions for oncology research and focus in other therapeutic areas.
Ultivue is based in Cambridge, MA. For more information, visit www.ultivue.com.
For Research Use Only. Not for use in diagnostic procedures.
Director, Business & Corporate Development